A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection

Spyros Papapetropoulos, Margaret S Lee, Stacey Boyer, Evan J Newbold, Spyros Papapetropoulos, Margaret S Lee, Stacey Boyer, Evan J Newbold

Abstract

Background: Essential tremor (ET) is a common, progressive neurological syndrome with bilateral upper-limb dysfunction of at least 3-year duration, with or without tremor in other body locations. This disorder has a negative impact on daily function and quality of life. A single oral therapy has been approved by FDA for ET. Off-label pharmacotherapies have inadequate efficacy and poor tolerability with high rates of patient dissatisfaction and discontinuation. Safe and efficacious pharmacotherapies are urgently needed to decrease tremor and improve daily living. T-CALM (Tremor-CAv3 modulation) protocol is designed to assess safety and efficacy of CX-8998, a selective modulator of the T-type calcium channel, for ET therapy. Methods/Design: T-CALM is a phase 2, proof of concept, randomized, double-blind, placebo-controlled trial. Titrated doses of CX-8998 to 10 mg BID or placebo will be administered for 28 days to moderate to severe ET patients who are inadequately treated with existing therapies. The primary endpoint will be change from baseline to day 28 of The Essential Tremor Rating Assessment Performance Subscale (TETRAS-PS). Secondary efficacy endpoints for clinician and patient perception of daily function will include TETRAS Activity of Daily Living (ADL), Quality of Life in Essential Tremor Questionnaire (QUEST), Clinical Global Impression-Improvement (CGI-I), Patient Global Impression of Change (PGIC), and Goal Attainment Scale (GAS). Kinesia One, Kinesia 360, and iMotor will biometrically evaluate motor function and tremor amplitude. Safety will be assessed by adverse events, physical and neurological exams and laboratory tests. Sample size of 43 patients per group is estimated to have 90% power to detect a 5.5-point difference between CX-8998 and placebo for TETRAS-PS. Efficacy analyses will be performed with covariance (ANCOVA) and 2-sided test at 0.05 significance level. Discussion: T-CALM has a unique design with physician rating scales, patient-focused questionnaires and scales and objective motor measurements to assess clinically meaningful and congruent efficacy. Patient perception of ET debilitation and therapy with CX-8998 will be key findings. Overall goal of T-CALM is generation of safety and efficacy data to support a go, no-go decision to further develop CX-8998 for ET. Design of T-CALM may guide future clinical studies of ET pharmacotherapies. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03101241.

Keywords: CX-8998; T-type calcium channel modulator; TETRAS; essential tremor; proof of concept.

Figures

Figure 1
Figure 1
Schematic of T-CALM Design.

References

    1. Haubenberger D, Hallett M. Essential tremor. N Engl J Med. (2018) 378:1802–10. 10.1056/NEJMcp1707928
    1. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus statement on the classification of tremors, from the task force on tremor of the international parkinsonian and movement disorder society. Mov Disord. (2018) 33:75–87. 10.1002/mds.27121
    1. Hopfner F, Helmich RC. The etiology of essential tremor: genes versus environment. Parkinsonism Relat Disord. (2018) 46(Suppl. ): S92–6. 10.1016/j.parkreldis.2017.07.014
    1. Hedera P, Cibulcik F, Davis TL. Pharmacotherapy of essential tremor. J Central Nerv Syst Dis. (2013) 5:43–55. 10.4137/JCNSD.S6561
    1. Iftinca MC. Neuronal T-type calcium channels: what's new? Iftinca: T-type channel regulation. J Med Life. (2011) 4:126–38. 10.1353/nhr.2011.0002
    1. Miwa H, Kondo T. T-type calcium channel as a new therapeutic target for tremor. Cerebellum. (2011) 10:563–569. 10.1007/s12311-011-0277-y
    1. Park Y-G, Kim J, Kim D. The potential roles of T-type Ca2+ channels in motor coordination. Front Neural Circuits. (2013) 7:172. 10.3389/fncir.2013.00172
    1. Marin-Lahoz J, Gironelli A. Linking essential tremor to the cerebellum: neurochemical evidence. Cerebellum. (2016) 15:243–52. 10.1007/s12311-015-0735-z
    1. Zamponi GW. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nat Rev Drug Discov. (2016) 15:19–34. 10.1038/nrd.2015.5
    1. Elble R, Bain P, Forjaz MJ, Haubenberger D, Testa C, Goetz CG, et al. . Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord. (2013) 28:1793–800. 10.1002/mds.25648
    1. Elble RJ. The essential tremor rating assessment scale. J Neurol Neuromed. (2016) 1:34–8. 10.29245/2572.942X/2016/4.1038
    1. Haubenberger D, Abbruzzese G, Bain PG, Bajaj N, Benito-Leon J, Bhatia KP, et al. . Transducer-based evaluation of tremor. Mov Disord. (2016) 31:1327–36. 10.1002/mds.26671
    1. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. (2010) 25:534–41. 10.1002/mds.22838
    1. Louis ED, Ottman R. How many people in the USA have essential tremor? Deriving a population estimate based on epidemiological data. Tremor Other Hyperkinet Mov. (2014) 4:259. 10.7916/D8TT4P4B
    1. Bain PG, Findley LJ, Thompson PD, Gresty MA, Rothwell JC, Harding AE, et al. . A study of hereditary essential tremor. Brain. (1994) 117(Pt 4):805–24. 10.1093/brain/117.4.805
    1. Lorenz D, Schweiger D, Moises H, Deuschl G. Quality of life and personality in essential tremor patients. Mov Disord. (2006) 21:1114–8. 10.1002/mds.20884
    1. Louis ED, Machado DG. Tremor-related quality of life: A comparison of essential tremor vs. Parkinson's disease patients. Parkinsonism Relat Disord. (2015) 21:729–35. 10.1016/j.parkreldis.2015.04.019
    1. Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB, Jr, et al. . Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. (2011) 77:1752–5. 10.1212/WNL.0b013e318236f0fd
    1. Bermejo-Pareja F, Puertas-Martin V. Cognitive features of essential tremor: a review of the clinical aspects and possible mechanistic underpinnings. Tremor Other Hyperkinet Mov. (2012) 2. 10.7916/D89W0D7W
    1. Chandran V, Pal PK, Reddy JY, Thennarasu K, Yadav R, Shivashankar N. Non-motor features in essential tremor. Acta Neurol Scand. (2012) 125:332–7. 10.1111/j.1600-0404.2011.01573.x
    1. Louis ED, Okun MS. It is time to remove the benign from the essential tremor label. Parkinsonism Relat Disord. (2011) 17:516–20. 10.1016/j.parkreldis.2011.03.012
    1. Critchley M. Observations on essential (heredofamial) tremor. Brain. (1949) 72(Pt 2):113–39. 10.1093/brain/72.2.113
    1. Louis ED, Frucht SJ, Rios E. Intention tremor in essential tremor: Prevalence and association with disease duration. Mov Disord. (2009) 24:626–7. 10.1002/mds.22370
    1. Cohen O, Pullman S, Jurewicz E, Watner D, Louis ED. Rest tremor in patients with essential tremor: prevalence, clinical correlates and electrophysiologic characteristics. Arch Neurol. (2003) 60:405–10. 10.1001/archneur.60.3.405
    1. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. Mov Disord. (1994) 9:193–6. 10.1002/mds.870090212
    1. Louis ED, Barnes L, Albert SM, Cote L, Schneier FR, Pullman SL, et al. . Correlates of functional disability in essential tremor. Mov Disord. (2001) 16:914–20. 10.1002/mds.1184
    1. Leegwater-Kim J, Louis ED, Pullman SL, Floyd AG, Borden S, Moskowitz CB, et al. . Intention tremor of the head in patients with essential tremor. Mov Disord. (2006) 21:2001–5. 10.1002/mds.21079
    1. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. Neuropsychiatr Dis Treat. (2010) 6:401–8. 10.2147/NDT.S4795
    1. Hedera P. Emerging strategies in the management of essential tremor. Ther Adv Neurol Disord. (2017) 10:137–48. 10.1177/1756285616679123
    1. Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, et al. . A randomized trial of focused ultrasound thalatomy for essential tremor. N Engl J Med. (2016) 375:730–9. 10.1056/NEJMoa1600159
    1. Zesiewicz TA, Kuo SH. Essential tremor. BMJ Clin Evid. (2015) 2015:1206.
    1. Inderal® (Propranolol Hydrochloride) Tablets FDA Package Insert. (2011). Ref ID 2919389.
    1. Louis ED. Treatment of essential tremor: are there issues we are overlooking? Front Neurol. (2011) 2:91. 10.3389/fneur.2011.00091
    1. Louis ED, Rohl B, Rice C. Defining the treatment gap: what essential tremor patients want they are not getting. Tremor Other Hyperkinet Mov. (2015) 5:331 10.7916/D87080M9
    1. Louis ED. Medication non-adherence in essential tremor. Parkinsonism Relat Disord. (2015) 21:138–41. 10.1016/j.parkreldis.2014.12.001
    1. Gribbs LL, Lee JH, Yang J, Satin J, Zhang J, Daud A, et al. Cloning and characterization of alpha 1H from human heart, a member of the T-type Ca2+ channel gene family. Circ Res. (1998) 83:103–9. 10.1161/01.RES.83.1.103
    1. Tai C, Yang Y, Pan M, Huang C, Kuo C. Modulation of subthalamic T-type Ca2+ channels remedies locomotor deficits in a rat model of Parkinson disease. J Clin Invest. (2011) 121:3289–305. 10.1172/JCI46482
    1. Park Y, Park H, Lee CJ, Choi S, Jo S, Choi H, et al. . Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive. Proc Natl Acad Sci USA. (2010) 107:10731–6. 10.1073/pnas.1002995107
    1. Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, et al. . Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. (2005) 24:315–24. 10.1038/sj.emboj.7600515
    1. Handforth A, Homanic GE, Covey DF, Krishnan K, Lee JY, Sahimura K, et al. . T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. Neuropharmacology. (2010) 59:380–7. 10.1016/j.neuropharm.2010.05.012
    1. Llinas RR. [Thalamo-cortical dysrhythmia syndrom: neuropsychiatric features] [Article in Spanish]. An R Acad Nac Med. (2003) 120:267–90.
    1. Llinas RR, Choi S, Urbano FJ, Shin H. γ-Band deficiency and abnormal thalamocortical activity in P/Q-type channel mutant mice. Proc Natl Acad Sci USA. (1999) 104:17819–24. 10.1073/pnas.0707945104
    1. Long MA, Deans MR, Paul DL, Connors BW. Rhythmicity without synchrony in the electrically uncoupled inferior olive. J Neurosci. (2002) 22:10898–905. 10.1523/JNEUROSCI.22-24-10898.2002
    1. Handforth A. Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor. Tremor Other Hyperkinet Mov. (2012) 2:1–14. 10.7916/D8TD9W2P
    1. Handforth A, Martin F, Kang G, Vanek Z. Zonisamide for essential tremor: an evaluator blinded study. Mov Disord. (2009) 24:437–40. 10.1002/mds.22418
    1. Chang K, Wang S, Chi C. Efficacy and safety of topiramate for essential tremor: a meta-analysis of randomized controlled trials. Medicine. (2015) 94:1–7. 10.1097/MD.0000000000001809
    1. Shipe W, Barrow J, Yang Z-Q, Lindsley C, Yang F, Schlegel K-A. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-Type Ca2+ channel antagonist. J. Med. Chem. (2008) 51:3692–5. 10.1021/jm800419w
    1. Lee M, Papapetropoulos S. CX-8998, a potent, selective T-type calcium channel antagonist dose-dependently suppresses seizures in the WAG/Rij genetic model of epilepsy. Neurology. (2018) 90(Suppl. 15):P5.281 Available online at:
    1. Lee M, Newbold E, Papapetropoulos S. Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel anatagonist in development for essential tremor and Parkinson's disease tremor in Cav3 driven neurological models. Mov Disord. (2018) 33(Suppl. 2). Available online at: (accessed May 29, 2019).
    1. Lee M, Maricich Y, Cavaletti G, Papapetropoulos S. Reversal of allodynia and neurophysiological outcomes by CX-8998, a potent, selective T-type calcium channel modulator, in a model of bortezomib induced peripheral neuropathy. Neurology. (2018) 15(Suppl.):S7.004 Available online at:
    1. Lee M, Newbold E, Papapetropoulos S. CX-8998 and CX-5395, potent, selective T-type calcium channel antagonists suppress seizures in genetic models of epilepsy. Soc Neurosci. (2018) 289.21. Available online at:
    1. Egan MF, Zhao X, Smith A, Troyer MD, Uebele VN, Pidkorytov V, et al. . Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. Hum Psychopharmacol. (2013) 28:124–33. 10.1002/hup.2289
    1. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, et al. . Reliability of a new scale for essential tremor. Mov Disord. (2012) 27:1567–9. 10.1002/mds.25162
    1. Hoffman J, McName J. Objective measure of upper extremity motor impairment in Parkinsons disease with inertial sensors. Conf Proc IEEE Eng Med Biol Soc. (2011) 2011:4378–81. 10.1109/IEMBS.2011.6091086
    1. Giufridda JP, Riley DE, Maddux BN, Heldman DA. Clinically deployable Kinesia technology for automated tremor assessment. Mov Disord. (2009) 24:723–30. 10.1002/mds.22445
    1. Heldman DA, Jankovic J, Vaillancourt DE, Prodoehl J, Elble RJ, Giufridda JP. Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. (2011) 17:537–42. 10.1016/j.parkreldis.2011.04.017
    1. Tröster AI, Pahwa R, Fields JA, Tanner CM, Lyons KE. Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation. Parkinsonism Relat Disord. (2005) 11:367–73. 10.1016/j.parkreldis.2005.05.009
    1. Guy W. Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; (1976).
    1. Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Commun Ment Health J. (1968) 4:443–53. 10.1007/BF01530764
    1. Pullam C, Eichenseer C, Goetz O, Waln C, Hunter C, Jankovic D, et al. Continuous in-home monitoring of essential tremor. Parkinsonism Relat Disord. (2014) 20:37–40. 10.1016/j.parkreldis.2013.09.009
    1. Mitsi G, Mendoza EU, Wissel BD, Barbopoulou E, Dwivedi AK, Tsoulos I, et al. Biometric digital health technology for measuring motor function in Parkinson's disease: results from a feasibility and patient satisfaction study. Front. Neurol. (2017) 13:273 10.3389/fneur.2017.00273
    1. Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M, et al. . The Columbia suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Pschiatry. (2011) 168:1266–77. 10.1176/appi.ajp.2011.10111704
    1. Kenderska T, Smith P, Bregnardello-Petersen R, Leung R, Tomlinson G. Evaluation of the measurement properties of the Epworth sleepiness scale: a systematic review. Sleep Med Rev. (2014) 18:321–31. 10.1016/j.smrv.2013.08.002
    1. Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D, et al. . A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol. (2008) 8:21. 10.1186/1471-2377-8-21
    1. Louis ED. Essential tremor and the cerebellum. Handb Clin Neurol. (2018) 155:245–58. 10.1016/B978-0-444-64189-2.00016-0
    1. Ondo W, Hashem V, LeWitt PA, Pahwa R, Shih L, Tarsy D, et al. . Comparison of the Fahn-Tolosa-Marin clinical rating scale and the essential tremor rating assessment scale. Mov Disord Clin Pract. (2018) 5:60–5. 10.1002/mdc3.12560
    1. Hess CW, Pullman SL. Tremor: clinical phenomenology and assessment techniques. Tremor Other Hyperkinet Mov. (2012) 2:1–15. 10.7916/D8WM1C41

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa